The deubiquitinating enzyme UCHL3 promotes anaplastic thyroid cancer progression and metastasis through Hippo signaling pathway
暂无分享,去创建一个
Y. Tao | D. Xiao | Shuang Liu | Jianing Tang | Gaosong Wu | Chao Mao | Ledu Zhou | Liang Xiao | Qiang Yang
[1] Yinlu Ding,et al. OTUB1 suppresses Hippo signaling via modulating YAP protein in gastric cancer , 2022, Oncogene.
[2] Jun Zhou,et al. MINDY1 promotes bladder cancer progression by stabilizing YAP , 2021, Cancer Cell International.
[3] Jianing Tang,et al. SOX13/TRIM11/YAP axis promotes the proliferation, migration and chemoresistance of anaplastic thyroid cancer , 2021, International journal of biological sciences.
[4] Junhu Wan,et al. YAP in pancreatic cancer: oncogenic role and therapeutic strategy , 2021, Theranostics.
[5] G. Blandino,et al. Endothelin-1 axis fosters YAP-induced chemotherapy escape in ovarian cancer. , 2020, Cancer letters.
[6] E. Sturgis,et al. Evaluation of Overall Survival in Patients With Anaplastic Thyroid Carcinoma, 2000-2019. , 2020, JAMA oncology.
[7] D. O'Brien,et al. The YAP-Interacting Phosphatase SHP2 Can Regulate Transcriptional Coactivity and Modulate Sensitivity to Chemotherapy in Cholangiocarcinoma , 2020, Molecular Cancer Research.
[8] Na Liu,et al. The deubiquitylase UCHL3 maintains cancer stem-like properties by stabilizing the aryl hydrocarbon receptor , 2020, Signal Transduction and Targeted Therapy.
[9] P. Ascierto,et al. PD-1 Blockade in Anaplastic Thyroid Carcinoma , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] S. Dogan,et al. Dissecting Anaplastic Thyroid Carcinoma (ATC): A Comprehensive Clinical, histologic, Immunophenotypic, and Molecular Study of 360 Cases. , 2020, Thyroid : official journal of the American Thyroid Association.
[11] I. Bahar,et al. EIF3H Orchestrates Hippo Pathway–Mediated Oncogenesis via Catalytic Control of YAP Stability , 2020, Cancer Research.
[12] Qiaojun He,et al. USP10 Promotes Proliferation of Hepatocellular Carcinoma by Deubiquitinating and Stabilizing YAP/TAZ , 2020, Cancer Research.
[13] Lidong Wang,et al. Regulation of Hippo/YAP signaling and Esophageal Squamous Carcinoma progression by an E3 ubiquitin ligase PARK2 , 2020, Theranostics.
[14] Jinbao Liu,et al. SRGN crosstalks with YAP to maintain chemoresistance and stemness in breast cancer cells by modulating HDAC2 expression , 2020, Theranostics.
[15] X. Yang,et al. Regulation of Hippo signaling and triple negative breast cancer progression by an ubiquitin ligase RNF187 , 2020, Oncogenesis.
[16] A. Pobbati,et al. A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy , 2020, Theranostics.
[17] Zihua Chen,et al. EphA2‐to‐YAP pathway drives gastric cancer growth and therapy resistance , 2020, International journal of cancer.
[18] Lidong Wang,et al. SHARPIN Inhibits Esophageal Squamous Cell Carcinoma Progression by Modulating Hippo Signaling , 2019, Neoplasia.
[19] Anping Li,et al. SIX1 Activates STAT3 Signaling to Promote the Proliferation of Thyroid Carcinoma via EYA1 , 2019, Front. Oncol..
[20] Yi Yang,et al. USP47-mediated deubiquitination and stabilization of YAP contributes to the progression of colorectal cancer , 2019, Protein & Cell.
[21] Jie Gao,et al. UCHL3 promotes ovarian cancer progression by stabilizing TRAF2 to activate the NF-κB pathway , 2019, Oncogene.
[22] Zhiwang Song,et al. UCHL3 promotes pancreatic cancer progression and chemo-resistance through FOXM1 stabilization. , 2019, American journal of cancer research.
[23] Chunling Yi,et al. YAP/TAZ Signaling and Resistance to Cancer Therapy. , 2019, Trends in cancer.
[24] Chen Ding,et al. OTUB2 Promotes Cancer Metastasis via Hippo-Independent Activation of YAP and TAZ. , 2019, Molecular cell.
[25] G. Halder,et al. Hippo–YAP/TAZ signalling in organ regeneration and regenerative medicine , 2018, Nature Reviews Molecular Cell Biology.
[26] J. Crawford,et al. Hippo pathway inhibition by blocking the YAP/TAZ–TEAD interface: a patent review , 2018, Expert opinion on therapeutic patents.
[27] T. Blundell,et al. The deubiquitylating enzyme UCHL3 regulates Ku80 retention at sites of DNA damage , 2018, Scientific Reports.
[28] R. Pili,et al. Crosstalk between Nrf2 and YAP contributes to maintaining the antioxidant potential and chemoresistance in bladder cancer , 2018, Free radical biology & medicine.
[29] M. Stuschke,et al. Anaplastic thyroid carcinoma: review of treatment protocols. , 2018, Endocrine-related cancer.
[30] Z. Lou,et al. The deubiquitinase USP9X promotes tumor cell survival and confers chemoresistance through YAP1 stabilization , 2017, Oncogene.
[31] M. Javid,et al. Epigenetic modifications in poorly differentiated and anaplastic thyroid cancer , 2017, Molecular and Cellular Endocrinology.
[32] A. Ribechini,et al. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies , 2017, Nature Reviews Endocrinology.
[33] A. H. Smits,et al. An Interaction Landscape of Ubiquitin Signaling. , 2017, Molecular cell.
[34] G. Mills,et al. Verteporfin inhibits YAP function through up-regulating 14-3-3σ sequestering YAP in the cytoplasm. , 2016, American journal of cancer research.
[35] B. Hinz,et al. YAP1 Is a Driver of Myofibroblast Differentiation in Normal and Diseased Fibroblasts. , 2015, The American journal of pathology.
[36] Bin Zhao,et al. Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer , 2015, Cell.
[37] A. Bauer,et al. YAP promotes proliferation, chemoresistance, and angiogenesis in human cholangiocarcinoma through TEAD transcription factors , 2015, Hepatology.
[38] T. Pawlik,et al. Emerging role of Hpo signaling and YAP in hepatocellular carcinoma , 2015, Journal of hepatocellular carcinoma.
[39] Q. Dou,et al. Deubiquitinases (DUBs) and DUB inhibitors: a patent review , 2015, Expert opinion on therapeutic patents.
[40] M. Karin,et al. A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis , 2015, Genes & development.
[41] Jae Eun Lee,et al. Ubiquitin C-terminal hydrolase-L3 regulates EMT process and cancer metastasis in prostate cell lines. , 2014, Biochemical and biophysical research communications.
[42] G. G. Galli,et al. The Hippo transducer YAP1 transforms activated satellite cells and is a potent effector of embryonal rhabdomyosarcoma formation. , 2014, Cancer cell.
[43] K. Guan,et al. The Hippo signaling pathway in stem cell biology and cancer , 2014, EMBO reports.
[44] Xin Zheng,et al. Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma , 2014, Molecular Cancer.
[45] Y. Nikiforov,et al. American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer. , 2012, Thyroid : official journal of the American Thyroid Association.
[46] Jun O. Liu,et al. Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. , 2012, Genes & development.
[47] C. Vandevoort,et al. Essential role of ubiquitin C‐terminal hydrolases UCHL1 and UCHL3 in mammalian oocyte maturation , 2012, Journal of cellular physiology.
[48] K. Latham,et al. Essential role of maternal UCHL1 and UCHL3 in fertilization and preimplantation embryo development , 2012, Journal of cellular physiology.
[49] S. Bicciato,et al. The Hippo Transducer TAZ Confers Cancer Stem Cell-Related Traits on Breast Cancer Cells , 2011, Cell.
[50] Je-Yoel Cho,et al. Ubiquitin C‐terminal hydrolase‐L3 regulates Smad1 ubiquitination and osteoblast differentiation , 2011, FEBS letters.
[51] X. Shen,et al. The potential role of ubiquitin c-terminal hydrolases in oncogenesis. , 2010, Biochimica et biophysica acta.
[52] K. Wada,et al. Ubiquitin carboxyl-terminal hydrolase l3 promotes insulin signaling and adipogenesis. , 2009, Endocrinology.
[53] Q. Zeng,et al. A role for TAZ in migration, invasion, and tumorigenesis of breast cancer cells. , 2008, Cancer research.
[54] M. Rapé,et al. Mechanism of Ubiquitin-Chain Formation by the Human Anaphase-Promoting Complex , 2008, Cell.
[55] E. Kebebew,et al. Anaplastic thyroid carcinoma , 2005, Cancer.
[56] Martin Rechsteiner,et al. Recognition of the polyubiquitin proteolytic signal , 2000, The EMBO journal.